GINAI
    News Wire
    Markets

    Here’s What Lifted Vertex Pharmaceuticals (VRTX) in Q4

    Yahoo FinanceJanuary 12, 2026 at 2:05 PMBullish1 min read

    Vertex Pharmaceuticals (VRTX) saw a strong performance in Q4, primarily driven by robust sales of its cystic fibrosis (CF) drugs. The company's innovative treatments in the CF space continue to demonstrate significant market penetration, contributing to its positive financial results for the quarter.

    Related Topics

    VRTXVertex PharmaceuticalsCystic FibrosisQ4 EarningsDrug Sales

    Related Articles

    Bitcoin Spikes Over $72K as Trump Announces Conditional Ceasefire With Iran

    neutral
    Yahoo Finance
    about 2 hours ago

    Trump’s Iran War Leaves the US Looking Weakened to Adversaries

    neutral
    Bloomberg
    about 2 hours ago

    1 S&P 500 Stock for Long-Term Investors and 2 We Ignore

    neutral
    Yahoo Finance
    about 2 hours ago

    China Trumpets ‘Own Efforts’ in Pushing For US-Iran Ceasefire

    neutral
    Bloomberg
    about 2 hours ago

    You May Also Like

    Bitcoin Spikes Over $72K as Trump Announces Conditional Ceasefire With Iran

    Yahoo Finance•about 2 hours ago

    Trump’s Iran War Leaves the US Looking Weakened to Adversaries

    Bloomberg•about 2 hours ago

    1 S&P 500 Stock for Long-Term Investors and 2 We Ignore

    Yahoo Finance•about 2 hours ago

    China Trumpets ‘Own Efforts’ in Pushing For US-Iran Ceasefire

    Bloomberg•about 2 hours ago

    Iran Ceasefire Deal Sends Wave of Relief Through Markets

    Bloomberg•about 2 hours ago

    3 Consumer Stocks with Questionable Fundamentals

    Yahoo Finance•about 2 hours ago